D espite recent advances in medical and interventional therapies, myocardial infarction (MI) continues to be a major cause of morbidity and mortality. 1,2 Furthermore, the ability to detect MI and its associated prognosis have evolved with the introduction of increasingly sensitive and myocardial tissue-specific cardiac biomarkers. 3, 4 Studies of percutaneous coronary intervention (PCI) with drug-eluting stent (DES) implantation have often focused on procedural MI. 5-7 Conversely, relatively little is known about the pathogenesis, frequency, predictors, and prognostic relevance of MI that occurs after successful PCI. We, therefore, evaluated the frequency, etiologies, and long-term outcomes Background-The frequency, causes, and impact of myocardial infarction (MI) after successful percutaneous coronary intervention have not been well studied.
Methods

Study Design and Population
The design, eligibility criteria, and end points from the ADAPT-DES study have been previously described. 8 In brief, 8582 consecutive patients at 11 US and German sites successfully treated with US Food and Drug Administration-or Conformité Européene (CE) markapproved DES were enrolled from July 2008 to September 2010, regardless of patient risk or lesion complexity. The only major exclusion criteria were the occurrence of major procedural complications or planned bypass surgery. Platelet reactivity was assessed post-PCI in all patients using the VerifyNow point-of-care assay (Accumetrics, San Diego, CA) after aspirin and thienopyridine loading. Aspirin was prescribed indefinitely, and a thienopyridine was recommended for ≥1 year. Clinical follow-up was performed at 30 days, 1 year, and 2 years. The rates of completed 1-year and 2-year follow-up were 98% and 89%, respectively, including 3.6% of patients who died within 2 years. The rate of lost-to-follow-up, withdrawal of consent, or refusal of contact at 2 years was 2.3%. The study was approved by the institutional review board at each participating center, and all eligible patients signed informed, written consent.
Definition and Classification of MI
For the present study, we excluded patients with periprocedural MI to examine the frequency, predictors, mechanisms, and prognostic implications of nonprocedure-related MI. Periprocedural MI was defined as a biomarker rise in creatine kinase, creatine kinase-myocardial band (MB), or troponin within 48 hours after the procedure as previously described. 8, 9 A nonprocedure-related MI was defined as a typical rise and fall of biochemical markers of myocardial necrosis (troponin or creatine kinase-MB) to greater than the local laboratory upper limit of normal with either ischemic symptoms, development of new pathological Q-waves, or electrocardiographic changes indicative of ischemia. 8, 9 Nonprocedural MIs were classified using a modification of the Third Universal Definition of MI: (1) spontaneous MI not related to the target lesion; (2) secondary or indeterminate MI; (3) stent thrombosis (ST)-related MI, and (4) in-stent restenosis (ISR)-related MI. 4 Spontaneous MI was defined as an acute ischemic event arising from a new lesion either in an untreated coronary artery or ≥10 mm from the index procedure target lesion as documented by coronary angiography. Secondary or indeterminate MI was defined as myocardial injury unrelated to unstable coronary artery disease either because of a supply/demand imbalance or of indeterminate pathogenesis. STrelated MI was defined as occurring secondary to definite or probable ST (Academic Research Consortium criteria). 10 ISR-related MI required angiographic confirmation of >70% diameter stenosis in or adjacent to (≤5 mm) a previously implanted stented without thrombus or a new more severe lesion outside the stent.
An independent committee adjudicated all MIs by reviewing hospital charts, electrocardiograms, coronary angiograms, and other data as required, classifying them as ST-related or non-ST-related. Non-ST-related MIs were then classified as spontaneous MI, secondary/ indeterminate MI, or ISR-related MI by 2 independent cardiologists (Drs Dohi and Maehara) using the above definitions.
Angiographic Analysis
Baseline procedural angiograms were evaluated by the investigators. Moderate or greater calcium was defined as readily visible densities noted within the vascular wall at the site of the stenosis. A bifurcation lesion had a side branch >1.5 mm in diameter. The angiographic pattern of ISR was classified according to Mehran et al. 11 
Statistical Analysis
Categorical variables were compared between groups by χ 2 or Fisher exact test. Continuous variables are presented as median with 25th and 75th percentiles and were compared using Kruskal-Wallis test. Time-to-event data are summarized as Kaplan-Meier estimates and were compared using the log-rank test. Time to MI event rates were estimated by the cumulative incidence function, accounting for the competing risk of all-cause death.
The predictors of any MI, each MI subtype, and death were identified by Cox proportional hazards regression. For each multivariable model, the variables were chosen based on their historical and pathophysiologic relationship to each event type, with 1 variable entered for ≈≥10 events in each model so as to avoid overfitting. The variables selected appear in the full model shown in Tables. For testing the relationship between all MI and each MI subtype and mortality, patients without any MI served as the control group in each model. MI was included as a time-dependent covariate in the mortality models. The proportional hazards assumption was verified by assessing Schoenfeld residuals. A P value <0.05 was considered significant for all analyses. Statistical analyses were performed using SAS version 9.1.3 (SAS Institute, Cary, NC). The competing risk plot was done using the R version 3.2.1 (R Foundation for Statistical Computing, Vienna, Austria) using the ggplot2 package version 1.0.0.
Results
Etiology and Frequency of Postprocedural MI
After eliminating 128 patients (1.5%) with a periprocedural MI, 8454 patients were included in the present analysis. MI during the 2-year follow-up period occurred in 263 patients (3.3%) at a median (25th, 75th percentiles) of 318 (129, 503) days after PCI. Patients with MI during follow-up were older and, at the time of the index PCI, were more likely to have diabetes mellitus, renal insufficiency, history of heart failure, prior revascularization procedures, and presented
WHAT IS KNOWN
• Myocardial infarction (MI) after drug-eluting stent (DES) implantation is a major cause of morbidity and mortality.
• The causes of MI after DES are multifactorial, and the prognostic implications of MI after DES may vary based on their mechanism.
WHAT THE STUDY ADDS
• In the contemporary era, nonprocedure-related MIs occur in 3.3% of patients within 2 years after successful DES implantation.
• Non-periprocedural MIs after DES implantation can be classified as stent thrombosis-related, in-stent restenosis-related, nontarget lesion-related, spontaneous, and secondary/indeterminate. In our study, 46% of non-periprocedural MIs were stent-related.
• Patients with a non-periprocedural MI had a 2.2× higher mortality than those who did not have an MI during the follow-up period. The highest risk of death was observed after nonprocedural MIs because of stent thrombosis.
with acute coronary syndromes (ACS) ( Among the 78 spontaneous MIs, 59 (75.6%) originated from a nontreated vessel, whereas 19 (24.4%) originated from a previously treated vessel either proximal (n=9) or distal to (n=10) an earlier target lesion. Among the 64 cases of secondary/indeterminate MI, a supply/demand imbalance was identified as the pathogenesis in 29 (45.3%), whereas the remainder was multifactorial or indeterminate ( Table 2 ). Among the 63 ST-related MIs, 51 (80.9%) arose from the segment of artery that was stented during the ADAPT-DES index procedure, whereas the remainder occurred in a segment stented in a procedure performed either before (n=9) or after (n=3) ADAPT-DES enrollment. Finally, among the 58 ISR-related MIs, 45 (77.6%) arose from the stented segment from the index ADAPT-DES procedure, whereas the rest occurred in a previously (n=11) or subsequently (n=2) stented segment. ISR lesions responsible for MI were classified as focal (<10 mm) in 31 (53.4%) cases, diffuse intra-stent in 19 (32.8%), diffuse proliferative in 4 (6.9%), and total occlusions in 4 (6.9%); the mean diameter stenosis was 82.8%±9.8%. In total, of the 263 MIs, the vessel of origin was an earlier treated target vessel in 115 cases (43.7%), a nontarget vessel in 84 cases (31.9%), and was indeterminate in origin in 64 cases (24.3%).
Timing of MI Occurrence
The time-to-event curves for all MI and the MI subtypes are shown in Figures 1 and 2 
Predictors of MI
As shown in Table 3 , after multivariable adjustment, significant predictors of MI included clinical and angiographic factors (ACS presentation, diabetes mellitus, current smoker, multivessel disease, treatment of an in-stent restenotic lesion), laboratory findings (low baseline hemoglobin and reduced creatinine clearance), antiplatelet agent-related factors (higher on-treatment platelet P2Y12 receptor reactivity and thienopyridine discontinuation within 6 months), and not being on a statin at discharge.
The multivariable predictors of follow-up MI varied according to the specific MI subtypes (Tables II-V in the Data  Supplement) . Spontaneous MI was associated with diabetes mellitus, presentation with ACS, no discharge statin use, high VerifyNow PRU, and premature dual antiplatelet therapy (DAPT) discontinuation. Secondary/indeterminate MI was associated with diabetes mellitus, history of heart failure, and low baseline hemoglobin. ST-related MI was associated with total stent length, high on-treatment platelet reactivity, and premature DAPT discontinuation. Finally, the only predictor of ISR-related MI identified was treatment with an in-stent restenotic lesion.
Impact on Mortality
Overall 2-year all-cause mortality was 3.9% (n=307). Patients who experienced an MI during follow-up had a significantly higher rate of 2-year mortality compared with those who did not (17.3% [42 deaths] versus 3.4% [265 deaths], P<0.001). Among the 64 cases of secondary/indeterminate MI, there was a significant difference in the 2-year mortality rate between the patients who experienced a secondary MI because of a supply/demand imbalance versus an indeterminate MI (26.8% versus 0%; P<0.001).
By multivariable analysis, the adjusted hazard ratio (95% confidence interval) for subsequent mortality during follow-up (Table 4 ).
Discussion
The major findings of the present report, the largest prospective study to date to examine the incidence, predictors, mechanisms, and implications of nonprocedural MI after PCI, are the following: (1) In the present study, spontaneous MI arising from previously untreated coronary segments (type 1 in the Third Universal Definition), 4 which are usually because of plaque rupture and thrombosis, accounted for only 30% of all MI events during the follow-up period in our study (absolute rate 1.0%). In the PROSPECT study, 1.3% of patients developed MI unrelated to initially treated target lesions at 3-year follow-up after successful PCI, 12 similar to the current study. The European Collaborative Project on Inflammation and Vascular Wall Remodeling in Atherosclerosis -Intravascular Ultrasound (AtheroRemo-IVUS) study also reported a <1% rate of nontarget lesion-related MIs at 1-year follow-up. 13 Thus, with high adherence to contemporary pharmacotherapy, spontaneous MIs arising from untreated nontarget lesions within the first several years after PCI is uncommon.
Of note, secondary MI (type 2 in the Third Universal Definition) 4 occurred almost as frequently as spontaneous MI during follow-up, although many of these were indeterminate in nature and not because of a documented supply/demand imbalance. Few previous studies examined the frequency of type 2 MIs. 14, 15 Morrow et al reported from a large ACS trial that only 3.5% of 1218 MIs after PCI were type 2, in contrast to 33% type 1 and 50% peri-procedure type 4a (periprocedural). 16 Conversely, our data are consistent with other prospective studies which reported type 2 MIs as responsible for 14% to 26% of all new MIs. 17, 18 Sabby et al reported that patients with type 2 MIs were older, more likely to be female, and have multiple comorbidities, consistent with our findings 17 ; however, the 19 Of note, stent-related issues (either ST or ISR) were responsible for nearly half of all MIs occurring during followup. Although ST is rare (and has decreased in incidence with contemporary DES), 20,21 its occurrence is often catastrophic, frequently resulting in extensive myonecrosis or death. 22 Despite the use of current generation DES in 64% of patients in ADAPT-DES, 24% of all non-periprocedural MIs through 2 years of follow-up in our study were ST-related (type 4b in the Third Universal Definition). 4 In the Drug Eluting Stent Event Registry of Thrombosis (DESERT), 23 the largest casecontrol registry of late/very late thrombosis after DES, 75% of ST events occurred after 1 year, similar to the 60% rate we observed. Furthermore, the clinical presentation of late/ very late ST events in DESERT was mainly ST-segmentelevation myocardial infarction (67%). In the present study, more than half of all ST-related MIs were Q-wave MIs, and subsequent mortality was increased 8-fold after an ST-related MI, the greatest hazard of any MI type. Thus, safer DES and more effective pharmacotherapies are required to eliminate ST. In the DAPT trial, 30 months compared with 12 months of DAPT reduced very late ST by 53%, an effect evident even in contemporary DES. 24 Although the efficacy of prolonged DAPT has varied in previous trials, [25] [26] [27] DAPT discontinuation before 6 months was a significant predictor of not only ST-related MIs, but also spontaneous MIs in the present study and effect also previously noted. 24 However, as prolonged DAPT increases bleeding and noncardiovascular mortality, 24 further studies are warranted to determine which patients have a net benefit from extending DAPT beyond 6 to 12 months.
For many years, it has been recognized that ISR can present as MI [28] [29] [30] (type 4c in the Third Universal Definition). 4 Dangas et al reported that 1% to 20% of DES ISR cases present as MI depending on the definition. 30 ISR presenting as MI is also predictive of future adverse events after ISR treatment. 31, 32 Delayed healing and persistent inflammation can induce neoatherosclerosis within stents which may present as ACS, which occurs earlier in DES than bare metal stents. [33] [34] [35] The findings of the present study that 22% of all MIs during follow-up were adjudicated as being caused by ISR again emphasizes the need for safer and more effective DES to improve late outcomes. The following variables were included in each multivariable model: age, sex, diabetes mellitus, body mass index, hypertension, hyperlipidemia, calculated creatinine clearance <60 mL/min, current smoking, prior MI, prior percutaneous coronary intervention, prior coronary artery bypass graft surgery, history of heart failure, presentation with an acute coronary syndrome, baseline hemoglobin, baseline white blood cell count, VerifyNow aspirin reaction units, VerifyNow P2Y12 reaction units, premature dual antiplatelet therapy discontinuation (within 6 mo), discharge use of an angiotensin converting enzyme inhibitor or angiotensin receptor blocker, discharge use of a beta blocker, discharge use of a statin, multivessel disease, vessel size, total stent length, and MI event as a time-adjusted covariate. Several recent studies did not identify MI after PCI as a significant predictor of long-term mortality. 36, 37 This issue is important because MI accounts for ≈45% of all primary end point composite events in contemporary randomized trials. 38 Surprisingly, however, in a recent review, only 3 of 80 trials (3.8%) differentiated periprocedural MI from non-periprocedural MI. 38 The prognostic implications of these MI types have been found to vary greatly. In the Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trial, MI occurring during the follow-up phase after PCI was a significant predictor of late mortality, whereas periprocedural MI was not. 39 Similar findings were reported from the Evaluation of Drug Eluting Stents and Ischemic Events (EVENT) registry. 40 In most studies, only very large periprocedural MIs have been associated with mortality. 5, 6 The present study underscores the strong relationship between non-periprocedural MI and subsequent mortality. Of note, however, of the 4 identified subtypes of nonprocedural MI, only MI because of ST and secondary/indeterminate causes were associated with mortality after multivariable adjustment. Even larger studies than ADAPT-DES are required to determine whether in the present era other nonprocedural MI etiologies significantly affect survival. These data further reinforce the importance of reporting MI rates by detailed pathogenesis, rather than just combining all MI types.
Table 4. Multivariable Adjusted Hazard Ratio and 95% Confidence Intervals for Death During Follow-Up in Patients Who Experienced Myocardial Infarction (MI) After Successful Percutaneous Coronary Intervention (PCI) With Drug-Eluting Stents, According to MI Etiology
Study Limitations
First, follow-up was truncated at 2 years, and the incidence and implications of MI occurring beyond this period are not known. Second, 2-year follow-up was completed in only 89% of patients, potentially reducing the precision of our results. Third, the 2-year rates of mortality (3.9%) and MI (3.3%) are lower than might have been expected, possibly because our study included only successful DES procedures without periprocedural MI. We also cannot exclude ascertainment bias resulting from variations in practice at different hospitals. MI presenting as sudden cardiac death might also have not been counted in the total. Fourth, other than ST-related MIs, the MI subclassification was conducted retrospectively, which might explain the relatively high proportion of secondary/indeterminate MIs. Fifth, despite angiographic review, some cases classified as ISR-related MI may have been because of thrombotic occlusion. Sixth, given the modest numbers of the different subtypes of MI (58-78 events each, limiting the number of variables that could be evaluated in multivariable analysis), we may not have identified all significant predictors of each MI class (in contrast to MI of any type, which had 263 events). Seventh, the small numbers of deaths in each category of MI type resulted in limited precision to estimate the relative mortality in each of these groups and low power to detect moderate-sized effects. Finally, all procedures in ADAPT-DES were clinically and angiographically successful, and collection of postprocedure troponin or creatine kinase-MB measurements was not systematically required, which likely explains the low (1.5%) rate of periprocedural MI.
Conclusions
Among patients undergoing successful PCI with DES implantation in the present multicenter study, although the frequency of non-periprocedural MI occurring during 2-year follow-up was relatively low, such events were significantly associated with subsequent mortality (especially MI because of ST and secondary/indeterminate causes). The different etiologies of non-periprocedural MI suggests that a multipronged approach to their prevention (cardiovascular risk factor reduction plus improved pharmacotherapy and safer DES) is necessary to further improve PCI outcomes. 
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